TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07160205: Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM

Sponsor: Restem, LLC. · Phase: PHASE2/PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 40 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$486,048

Rescue Site Savings

+$324,032

Unlock Full NCT07160205 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07160205 Rescue Dossier →